Concord Biotech’s IPO to open on 4th August, 2023

The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy

Biogen to acquire Reata Pharmaceuticals

Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth

USFDA accepts biologics license application for GC Biopharma's GC5107B

New products and nutraceuticals added under Jan Aushadhi Pariyojana

The product basket increased to 1800 medicines and 285 Surgical Equipment

AiMeD expresses dismay over FICCI’s ‘Un-Make in India’ drive

Unfortunate to see PM’s ‘Make in India’ dream being bulldozed

Upsurge in pink eye conjunctivitis cases in the country

Take proper precautions and seek timely treatment!

Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer

Marks the World Head & Neck Cancer Day at the OCTF Conference

Eugia Pharma receives USFDA approval for Plerixafor Injection

The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023

TransCure bioServices partners with Preclina to expands reach into APAC

Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders